PLZF與annexin A1在PPARα訊號路徑中對減緩糖尿病腎小管病變所扮演的角色

Medicine and Dentistry

1. Lipocortin 1 100%
2. Kidney Tubule Disorder 100%
3. Signal Transduction 100%
4. Peroxisome Proliferator Activated Receptor Alpha 100%
5. Advanced Glycation End-Product 53%
6. Zinc Finger and BTB Domain Containing Protein 16 46%
7. Autophagy 33%
8. Diabetic Nephropathy 26%
9. Diseases 13%
10. Kidney Function 13%
11. Epithelial Cell 13%
12. Long Chain Fatty Acid 6%
13. Proteinuria 6%
14. Knockout Mouse 6%
15. Streptozocin 6%
16. Complications of Diabetes Mellitus 6%
17. Cell Nucleus Receptor 6%
18. In Vitro 6%
19. Nicotinamide 6%
20. Diabetes 6%
21. Prevalence 6%
22. Nephropathy 6%
23. Biomedical Research 6%
24. Public Health 6%
25. Protein Expression 6%
26. Maturity Onset Diabetes of the Young 6%
27. Glomerulus 6%
28. down Regulation 6%
29. Kidney Fibrosis 6%
30. Fibrosis 6%
31. Cytokine 6%
32. Diabetes Mellitus 6%
33. End Stage Renal Disease 6%
34. Fatty Acid 6%
35. Transcription Factors 6%
36. Therapeutic Target 6%
37. Homeostasis 6%
38. Upregulation 6%

Pharmacology, Toxicology and Pharmaceutical Science

1. Peroxisome Proliferator Activated Receptor Alpha 100%
2. Lipocortin 1 100%
3. Kidney Tubule Disorder 100%
4. Advanced Glycation End Product 53%
5. Zinc Finger and BTB Domain Containing Protein 16 46%
6. Diabetic Nephropathy 26%
7. Mouse Model 13%
8. Fibrosis 13%
9. Diseases 13%
10. Rat 13%
11. Nicotinamide 6%
12. Long Chain Fatty Acid 6%
13. Transcription Factors 6%
14. Diabetic Complication 6%
15. Prevalence 6%
16. End Stage Renal Disease 6%
17. Diabetes Mellitus 6%
18. Streptozotocin 6%
19. Knockout Mouse 6%
20. Fatty Acid 6%
21. Cell Nucleus Receptor 6%
22. Cytokine 6%
23. Proteinuria 6%
24. Maturity Onset Diabetes of the Young 6%
25. Kidney Disease 6%